Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020473 (
hyperlipidemia
)
15,891
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Resistin and resistin-like molecules (RELMs) are a family of proteins reportedly related to insulin resistance and inflammation. Because the serum concentration and intestinal expression level of
RELMbeta
were elevated in insulin-resistant rodent models, in this study we investigated the effect of
RELMbeta
on insulin signaling and metabolism using transgenic mice and primary cultured hepatocytes. First, transgenic mice with hepatic
RELMbeta
overexpression were shown to exhibit significant hyperglycemia,
hyperlipidemia
, fatty liver, and pancreatic islet enlargement when fed a high fat diet. Hyperinsulinemic glucose clamp showed a decreased glucose infusion rate due to increased hepatic glucose production. In addition, the expression levels of IRS-1 and IRS-2 proteins as well as the degrees of insulin-induced phosphatidylinositol 3-kinase and Akt activations were attenuated in
RELMbeta
transgenic mice. Similar down-regulations of IRS-1 and IRS-2 proteins were observed in primary cultured hepatocytes chronically treated (for 24 h) with
RELMbeta
, suggesting the insulin resistance-inducing effect of
RELMbeta
to be direct. Furthermore, it was shown that
RELMbeta
acutely and markedly activates ERK and p38, while weakly activating JNK, in primary cultured hepatocytes. This increased basal p38 phosphorylation level was also observed in the livers of
RELMbeta
transgenic mice. In conclusion,
RELMbeta
, a gut-derived hormone, impairs insulin signaling probably via the activations of classic MAPKs, and increased expression of
RELMbeta
may be involved in the pathogenesis of glucose intolerance and
hyperlipidemia
in some insulin-resistant models. Thus,
RELMbeta
is a potentially useful marker for assessing insulin resistance and may also be a target for future novel anti-diabetic agents.
...
PMID:Resistin-like molecule beta activates MAPKs, suppresses insulin signaling in hepatocytes, and induces diabetes, hyperlipidemia, and fatty liver in transgenic mice on a high fat diet. 1624 41